AMRXAmneal Pharmaceuticals, Inc.
Is the price fair?
Neither cheap nor expensive: cheap vs its sector, but priced for +18% a year vs +10% a year delivered.
Priced for ~18% a year FCF growth. The price demands more than its three-year revenue growth of 10% a year, priced for acceleration.
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What AMRX's price assumes
Amneal Pharmaceuticals, Inc. trades at 41.6× earnings against 21.0× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 21.0 · 1.98× the median: the market pays up for this one
- Price / sales
- 2.09
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 2.0%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +18%
Growth the price implies · The price pays for +18% free cash flow growth a year for a decade; the business has delivered −4.4% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 197
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 19.9
- EV / salestoday's price, trailing year to Jun 30, 2026
- 2.90
- Healthcare median P/E503 names
- 27.9
- Drug Manufacturers - Specialty & Generic median P/E44 names
- 21.0
- Free cash flow, trailing twelve months
- $128M
- Market capitalisation319.4 million shares, counted Jul 31, 2026
- $6.51B
- 3-year revenue growth
- +10%
- 3-year free cash flow growth
- −4.4%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Drug Manufacturers, Specialty & Generic
Ranks #16 of 39 by RyuScore